Complete contrast staining of hepatocellular carcinoma during drug-eluting bead chemoembolization predicts a favorable response.

IF 1.1 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of Clinical Imaging Science Pub Date : 2024-11-27 eCollection Date: 2024-01-01 DOI:10.25259/JCIS_129_2024

Sultan R Alharbi

{"title":"Complete contrast staining of hepatocellular carcinoma during drug-eluting bead chemoembolization predicts a favorable response.","authors":"Sultan R Alharbi","doi":"10.25259/JCIS_129_2024","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was to evaluate complete contrast staining (CCS) of HCC during drug-eluting bead transarterial chemoembolization (DEBTACE) first session for response prediction.Methods: Forty-one patients with solitary HCC who underwent DEBTACE were retrospectively enrolled and divided into two groups based on contrast staining of HCC using two-dimensional (2D) fluoroscopy during the first session of DEBTACE. Both groups underwent one or two sessions of DEBTACE to achieve a complete response. Responses were evaluated using the modified Response Evaluation Criteria in Solid Tumors. A comparison of the complete response between the CCS and non-CCS groups was performed, and the prediction value was studied.Results: CCS in 2D fluoroscopy during the first session of drug-eluting bead chemoembolization was observed in 22 (53.7%) patients. Well-defined HCC and super-selective chemoembolization were significantly associated with CCS. Complete response was observed in 54.54%, 90%, and 95.45% of CCS patient groups after the first session, second session, and cumulative sessions of TACE, respectively. Complete responses were 10.52%, 29.41%, and 36.84% in the non-CCS group after the first, second, and cumulative sessions of TACE, respectively.Conclusion: CCS of HCC using 2D fluoroscopy during DEBTACE is a predictor of a favorable response after two sessions of treatment.","PeriodicalId":15512,"journal":{"name":"Journal of Clinical Imaging Science","volume":"14 ","pages":"46"},"PeriodicalIF":1.1000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618748/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Imaging Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/JCIS_129_2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The objective of this study was to evaluate complete contrast staining (CCS) of HCC during drug-eluting bead transarterial chemoembolization (DEBTACE) first session for response prediction.

Methods: Forty-one patients with solitary HCC who underwent DEBTACE were retrospectively enrolled and divided into two groups based on contrast staining of HCC using two-dimensional (2D) fluoroscopy during the first session of DEBTACE. Both groups underwent one or two sessions of DEBTACE to achieve a complete response. Responses were evaluated using the modified Response Evaluation Criteria in Solid Tumors. A comparison of the complete response between the CCS and non-CCS groups was performed, and the prediction value was studied.

Results: CCS in 2D fluoroscopy during the first session of drug-eluting bead chemoembolization was observed in 22 (53.7%) patients. Well-defined HCC and super-selective chemoembolization were significantly associated with CCS. Complete response was observed in 54.54%, 90%, and 95.45% of CCS patient groups after the first session, second session, and cumulative sessions of TACE, respectively. Complete responses were 10.52%, 29.41%, and 36.84% in the non-CCS group after the first, second, and cumulative sessions of TACE, respectively.

Conclusion: CCS of HCC using 2D fluoroscopy during DEBTACE is a predictor of a favorable response after two sessions of treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝细胞癌在药物洗脱珠化疗栓塞期间的完全对比染色预测良好的反应。

目的：本研究的目的是评估HCC在药物洗脱经动脉化疗栓塞（DEBTACE）第一次疗程中的完全对比染色（CCS）以预测反应。方法：回顾性纳入41例行DEBTACE的孤立性HCC患者，并根据DEBTACE第一次期间使用二维（2D）透视对HCC的对比染色分为两组。两组患者均接受一到两次DEBTACE治疗以达到完全缓解。使用修改后的实体瘤反应评价标准对反应进行评价。比较CCS组和非CCS组的完全反应，并研究其预测值。结果：22例（53.7%）患者在第一次药物洗脱珠状化疗栓塞期间的二维透视中观察到CCS。明确的HCC和超选择性化疗栓塞与CCS显著相关。在第一次TACE治疗、第二次TACE治疗和累计TACE治疗后，54.54%、90%和95.45%的CCS患者组出现完全缓解。在第一次、第二次和累计TACE治疗后，非ccs组的完全缓解率分别为10.52%、29.41%和36.84%。结论：在DEBTACE期间使用二维透视检查HCC的CCS是两个疗程治疗后良好反应的预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Clinical Imaging Science RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： The Journal of Clinical Imaging Science (JCIS) is an open access peer-reviewed journal committed to publishing high-quality articles in the field of Imaging Science. The journal aims to present Imaging Science and relevant clinical information in an understandable and useful format. The journal is owned and published by the Scientific Scholar. Audience Our audience includes Radiologists, Researchers, Clinicians, medical professionals and students. Review process JCIS has a highly rigorous peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts, affiliations and financial associations such that the published content is not biased.